BiotechTube
Curematch

Curematch

San Diego, United States· Est.
curematch.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

Curematch operates in the diagnostics and genomics sector, offering a software-as-a-service platform that uses proprietary algorithms to analyze complex cancer biomarker data and recommend ranked, genomically-matched combination therapies. A key commercial milestone is the granting of a Category III CPT code (0794T) for its service, facilitating reimbursement and broader clinical adoption. The company's value proposition is supported by published research, including the I-PREDICT study, suggesting improved progression-free survival for patients on combination therapies selected via high matching scores. Curematch targets oncologists, cancer centers, and NGS labs as its primary customers.

Oncology

Technology Platform

Proprietary rules-based algorithm that analyzes genomic and proteomic biomarker data from tumor samples to rank and score personalized combination therapies from FDA-approved and investigational drugs.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

The establishment of a dedicated CPT code (0794T) creates a clear reimbursement pathway, enabling broader adoption by oncologists and integration into standard care.
The growing volume of molecular tumor profiling generates an increasing need for interpretive tools, expanding the addressable market.
Partnerships with NGS labs, pharma companies, and payers present avenues for growth and data network effects.

Risk Factors

Clinical adoption depends on generating more prospective data proving improved patient outcomes.
Reimbursement is not guaranteed despite the CPT code, as payers may set low rates or impose barriers.
The company faces competition from other clinical decision support platforms and must continuously update its knowledge base to remain current.

Competitive Landscape

Curematch competes in the clinical decision support software market for oncology, which includes companies like Tempus, Foundation Medicine (FM Ingenuity), IBM Watson Health (formerly), and various academic medical center-derived tools. Its specific focus on scoring and ranking combination therapies, rather than just single-agent matches, is a key differentiator. Competition is based on algorithm sophistication, clinical validation, ease of integration, and payer coverage.

More companies in Diagnostics & Precision Medicine →More companies in United States →